808 related articles for article (PubMed ID: 17903394)
21. Taxanes in the adjuvant treatment of breast cancer: why not yet?
Piccart MJ; Lohrisch C; Duchateau L; Buyse M
J Natl Cancer Inst Monogr; 2001; (30):88-95. PubMed ID: 11773299
[TBL] [Abstract][Full Text] [Related]
22. Taxane containing regimens for metastatic breast cancer.
Ghersi D; Wilcken N; Simes J; Donoghue E
Cochrane Database Syst Rev; 2005 Apr; (2):CD003366. PubMed ID: 15846659
[TBL] [Abstract][Full Text] [Related]
23. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.
Collins R; Fenwick E; Trowman R; Perard R; Norman G; Light K; Birtle A; Palmer S; Riemsma R
Health Technol Assess; 2007 Jan; 11(2):iii-iv, xv-xviii, 1-179. PubMed ID: 17181985
[TBL] [Abstract][Full Text] [Related]
24. Taxane containing regimens for metastatic breast cancer.
Ghersi D; Wilcken N; Simes J; Donoghue E
Cochrane Database Syst Rev; 2003; (3):CD003366. PubMed ID: 12917963
[TBL] [Abstract][Full Text] [Related]
25. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
26. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
27. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer.
Nowak AK; Wilcken NR; Stockler MR; Hamilton A; Ghersi D
Lancet Oncol; 2004 Jun; 5(6):372-80. PubMed ID: 15172358
[TBL] [Abstract][Full Text] [Related]
28. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Takashima T; Mukai H; Hara F; Matsubara N; Saito T; Takano T; Park Y; Toyama T; Hozumi Y; Tsurutani J; Imoto S; Watanabe T; Sagara Y; Nishimura R; Shimozuma K; Ohashi Y;
Lancet Oncol; 2016 Jan; 17(1):90-8. PubMed ID: 26617202
[TBL] [Abstract][Full Text] [Related]
29. Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions.
Dang CT
Expert Rev Anticancer Ther; 2006 Mar; 6(3):427-36. PubMed ID: 16503859
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
31. Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
Rodgers M; Soares M; Epstein D; Yang H; Fox D; Eastwood A
Health Technol Assess; 2011 May; 15 Suppl 1():1-12. PubMed ID: 21609648
[TBL] [Abstract][Full Text] [Related]
32. The role of taxanes in the treatment of breast cancer.
Nabholtz JM; Gligorov J
Expert Opin Pharmacother; 2005 Jun; 6(7):1073-94. PubMed ID: 15957963
[TBL] [Abstract][Full Text] [Related]
33. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
Leung PP; Tannock IF; Oza AM; Puodziunas A; Dranitsaris G
J Clin Oncol; 1999 Oct; 17(10):3082-90. PubMed ID: 10506603
[TBL] [Abstract][Full Text] [Related]
34. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients.
Bria E; Nistico C; Cuppone F; Carlini P; Ciccarese M; Milella M; Natoli G; Terzoli E; Cognetti F; Giannarelli D
Cancer; 2006 Jun; 106(11):2337-44. PubMed ID: 16649217
[TBL] [Abstract][Full Text] [Related]
35. Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.
Lamb HM; Wiseman LR
Pharmacoeconomics; 1998 Oct; 14(4):447-59. PubMed ID: 10344911
[TBL] [Abstract][Full Text] [Related]
36. [Development of docetaxel in the adjuvant chemotherapy of breast cancer].
Fattoruso SI; Rossi S; Di Lauro L; Botti C; Vici P; Lopez M
Clin Ter; 2008; 159(5):369-76. PubMed ID: 18998039
[TBL] [Abstract][Full Text] [Related]
37. Controversies in the management of adjuvant breast cancer with taxanes: review of the current literature.
Araque Arroyo P; Ubago Pérez R; Cancela Díez B; Fernández Feijóo MA; Hernández Magdalena J; Calleja Hernández MA
Cancer Treat Rev; 2011 Apr; 37(2):105-10. PubMed ID: 20655664
[TBL] [Abstract][Full Text] [Related]
38. Cost effectiveness of treatment options in advanced breast cancer in the UK.
Brown RE; Hutton J; Burrell A
Pharmacoeconomics; 2001; 19(11):1091-102. PubMed ID: 11735676
[TBL] [Abstract][Full Text] [Related]
39. The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation.
Takeda AL; Jones J; Loveman E; Tan SC; Clegg AJ
Health Technol Assess; 2007 May; 11(19):iii, ix-xi, 1-62. PubMed ID: 17462169
[TBL] [Abstract][Full Text] [Related]
40. Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa.
Alshreef A; MacQuilkan K; Dawkins B; Riddin J; Ward S; Meads D; Taylor M; Dixon S; Culyer AJ; Ruiz F; Chalkidou K; Edoka I
Value Health Reg Issues; 2019 Sep; 19():65-74. PubMed ID: 31096179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
